| NCT ID | NCT06795893 |
| Status | Recruiting |
| Phase | — |
| Sponsor | AstraZeneca |
| Condition | Systemic Lupus Erythematosus |
| Study Type | OBSERVATIONAL |
| Enrollment | 240 participants |
| Start Date | 2025-11-07 |
| Primary Completion | 2031-04-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 240 participants in total. It began in 2025-11-07 with a primary completion date of 2031-04-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Pregnancy and infant outcomes in anifrolumab exposed pregnancies using PRegnancy outcomes Intensive Monitoring (PRIM) data: The anifrolumab PRIM program
Eligibility Criteria
Inclusion Criteria: * Currently or recently (within 1 year of pregnancy outcome) pregnant * Exposure to at least 1 dose of anifrolumab at any time during pregnancy or in the 16 weeks prior to date of conception Exclusion Criteria: * Pregnancy cases that have been enrolled in the prospective pregnancy registry (D3461R00051), those reported prior to the start of the PRIM program, or those that have been exposed to known teratogens or investigational medications will be excluded from the anifrolumab PRIM study.
Contact & Investigator
Syd Philips
PRINCIPAL INVESTIGATOR
PPD Miami, US
Frequently Asked Questions
Who can join the NCT06795893 clinical trial?
This trial is open to female participants only, studying Systemic Lupus Erythematosus. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06795893 currently recruiting?
Yes, NCT06795893 is actively recruiting participants. Contact the research team at information.center@astrazeneca.com for enrollment information.
Where is the NCT06795893 trial being conducted?
This trial is being conducted at Södertälje, Sweden.
Who is sponsoring the NCT06795893 clinical trial?
NCT06795893 is sponsored by AstraZeneca. The principal investigator is Syd Philips at PPD Miami, US. The trial plans to enroll 240 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.